How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
ALISO VIEJO, Calif., March 8 /PRNewswire - FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has reached agreement to sell its ACIS(R) and Trestle(R) Instrument Systems business assets and related intellectual property to Carl Zeiss MicroImaging,Inc. for
Novel markers, or biomarkers, are characteristics of an individual's tumoror disease that, once identified and quantified, allow for more accurate prognosis, diagnosis and treatment. The growing demand for personalized medicine has generated a need for these novel diagnostics, creating a new market expected to reach
"The timing for this sale is ideal, and Zeiss is the perfect partner," commented Clarient President and CEO Ron Andrews . "We have diligently planned and executed Clarient's transformation into a leading diagnostic services company. This transaction enables us to explore greater opportunities without the financial limitations that have restrained us in recent years. Additionally, we believe that our relationship with Zeiss will provide us access to the critical technologies that we need to develop novel markers, which will ultimately be used to monitor cancer and tailor individualized therapies."
Under the agreement, Clarient retains access to the intellectual property related to the image analysis and application development software. The agreement also includes a royalty-free cross license to Clarient with respect to certain of the transferred intellectual property to develop new tests and capabilities for Clarient's laboratory services (including the ACIS platform). These activities will be done exclusively on Zeiss equipment and will support the continued development of Systems offered by Zeiss.
"This transaction will allow each company to focus on strengthening their individual businesses and create growth synergies that will enhance the success of both companies," continued Andrews. "Zeiss is a world-class organization with a strong history of innovation in the area of microscopy and laser micro-dissection. This transaction significantly strengthens Clarient's balance sheet and provides the financial flexibility for Clarient to reach break even in cash flow from operations by year end and make key investments in technologies and tests that will further distinguish the current laboratory services business in a rapidly evolving marketplace."